Keverprazan Hydrochloride: First Approval

Drugs. 2023 May;83(7):639-643. doi: 10.1007/s40265-023-01865-w.

Abstract

Keverprazan hydrochloride () is a potassium ion competitive acid blocker that is being developed by Jiangsu Carephar Pharmaceuticals for the treatment of acid-related disease. Keverprazan hydrochloride was recently approved in China for the treatment of adults with reflux oesophagitis or duodenal ulcer. This article summarizes the milestones in the development of keverprazan hydrochloride leading to this first approval for reflux oesophagitis and duodenal ulcer.

Publication types

  • Review

MeSH terms

  • Adult
  • China
  • Duodenal Ulcer*
  • Esophagitis, Peptic*
  • Helicobacter Infections*
  • Humans